(cabozantinib)

Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC

Shots: The company has completed the enrolment in the P-III CONTACT-01 trial evaluating cabozantinib + atezolizumab in a ratio (1:1) in 366 patients with metastatic NSCLC prior treated with an immune checkpoint inhibitor & Pt-containing CT. The study is sponsored by Roche & co-funded by Exelixis The 1EPs of a trial are OS & 2EPs …

Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC Read More »

Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory DTC at ESMO 2021

Shots: The P-III COSMIC-311 trial evaluates Cabometyx (60mg, qd) vs PBO in a ratio (2:1) in 258 patients aged ≥12yrs. with previously treated radioactive iodine-refractory DTC across 164 sites globally An updated analysis showed ORR (11% vs 0%) as assessed by BIRC in ITT population including 1 CR, m-OS (19.4mos.) for Cabometyx but not estimable …

Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory DTC at ESMO 2021 Read More »

Exelixis’ Cabometyx (cabozantinib) Receives the US FDA’s Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer

Shots: The approval is based on P-III COSMIC-311 evaluating Cabometyx (60mg, qd) vs PBO in a ratio (2:1) in 258 patients aged ≥12yrs. with radioactive iodine-refractory DTC who progressed after up to two prior VEGFR-targeted therapies across 164 sites globally At a planned interim analysis, the therapy demonstrated the reduction in the risk of disease …

Exelixis’ Cabometyx (cabozantinib) Receives the US FDA’s Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer Read More »

BMS’ Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP’s Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

Shots: The CHMP recommendation is based on P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC The P-III result showed improvements in PFS, OS and ORR with consistent efficacy benefits observed across key subgroups of patients and was well tolerated, with a low …

BMS’ Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP’s Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma Read More »